

Supplementary Table 3. Incidence Rates (Unique Patients with Events Per 100 Patient-Years) for Herpes Zoster in the JMDC and MDV Databases

Group	JMDC			MDV		
	No.	PY	IR (95% CI)	No.	PY	IR (95% CI)
Group 1 (CS, IM, or TNFi)						
Male	22	1,471.42	1.50 (0.87–2.12)	83	9,288.42	0.89 (0.70–1.09)
Female	20	839.25	2.38 (1.34–3.43)	80	6,996.58	1.14 (0.89–1.39)
<35 yr	9	696.67	1.29 (0.45–2.14)	31	3,910.67	0.79 (0.51–1.07)
≥35 yr	33	1,614.00	2.05 (1.35–2.74)	132	12,374.33	1.07 (0.89–1.25)
<50 yr	27	1,663.67	1.62 (1.01–2.24)	69	8,841.00	0.78 (0.60–0.97)
≥50 yr	15	647.00	2.32 (1.15–3.49)	94	7,444.00	1.26 (1.01–1.52)
<65 yr	42	2,251.17	1.87 (1.30–2.43)	118	13,248.58	0.89 (0.73–1.05)
≥65 yr	0	59.50	0.00 (0.00–0.00)	45	3,036.42	1.48 (1.05–1.92)
Group 2 (IM)						
Male	5	773.42	0.65 (0.08–1.21)	29	4,992.42	0.58 (0.37–0.79)
Female	8	447.58	1.79 (0.55–3.03)	40	3,681.75	1.09 (0.75–1.42)
<35 yr	4	324.25	1.23 (0.03–2.44)	10	1,921.08	0.52 (0.20–0.84)
≥35 yr	9	896.75	1.00 (0.35–1.66)	59	6,753.08	0.87 (0.65–1.10)
<50 yr	7	823.33	0.85 (0.22–1.48)	25	4,553.00	0.55 (0.33–0.76)
≥50 yr	6	397.67	1.51 (0.30–2.72)	44	4,121.17	1.07 (0.75–1.38)
<65 yr	13	1,188.58	1.09 (0.50–1.69)	46	7,110.17	0.65 (0.46–0.83)
≥65 yr	0	32.42	0.00 (0.00–0.00)	23	1,564.00	1.47 (0.87–2.07)
Group 2-1 (TAC or CyA)						
Male	1	20.50	4.88 (0.00–14.44)	2	145.50	1.38 (0.00–3.28)
Female	0	34.67	0.00 (0.00–0.00)	9	260.42	3.46 (1.20–5.71)
<35 yr	1	5.50	18.18 (0.00–53.82)	1	48.33	2.07 (0.00–6.12)
≥35 yr	0	49.67	0.00 (0.00–0.00)	10	357.58	2.80 (1.06–4.53)
<50 yr	1	29.17	3.43 (0.00–10.15)	3	144.67	2.07 (0.00–4.42)
≥50 yr	0	26.00	0.00 (0.00–0.00)	8	261.25	3.06 (0.94–5.18)
<65 yr	1	50.17	1.99 (0.00–5.90)	8	242.33	3.30 (1.01–5.59)
≥65 yr	0	5.00	0.00 (0.00–0.00)	3	163.58	1.83 (0.00–3.91)
Group 2-2 (6-MP or AZA)						
Male	4	752.92	0.53 (0.01–1.05)	27	4,846.92	0.56 (0.35–0.77)
Female	8	412.92	1.94 (0.60–3.28)	31	3,421.33	0.91 (0.59–1.23)
<35 yr	3	318.75	0.94 (0.00–2.01)	9	1,872.75	0.48 (0.17–0.80)
≥35 yr	9	847.08	1.06 (0.37–1.76)	49	6,395.50	0.77 (0.55–0.98)
<50 yr	6	794.17	0.76 (0.15–1.36)	22	4,408.33	0.50 (0.29–0.71)
≥50 yr	6	371.67	1.61 (0.32–2.91)	36	3,859.92	0.93 (0.63–1.24)
<65 yr	12	1,138.42	1.05 (0.46–1.65)	38	6,867.83	0.55 (0.38–0.73)
≥65 yr	0	27.42	0.00 (0.00–0.00)	20	1,400.42	1.43 (0.80–2.05)

(Continued to the next page)

Supplementary Table 3. Continued

Group	JMDC			MDV		
	No.	PY	IR (95% CI)	No.	PY	IR (95% CI)
Group 3 (TNFi)						
Male	7	251.83	2.78 (0.72–4.84)	8	1,225.33	0.65 (0.20–1.11)
Female	3	138.92	2.16 (0.00–4.60)	10	1,207.08	0.83 (0.32–1.34)
<35 yr	0	134.67	0.00 (0.00–0.00)	3	662.50	0.45 (0.00–0.97)
≥35 yr	10	256.08	3.91 (1.49–6.33)	15	1,769.92	0.85 (0.42–1.28)
<50 yr	4	304.42	1.31 (0.03–2.60)	9	1,443.92	0.62 (0.22–1.03)
≥50 yr	6	86.33	6.95 (1.39–12.51)	9	988.50	0.91 (0.32–1.51)
<65 yr	10	382.75	2.61 (0.99–4.23)	12	2,006.08	0.60 (0.26–0.94)
≥65 yr	0	8.00	0.00 (0.00–0.00)	6	426.33	1.41 (0.28–2.53)
Group 4 (IM and TNFi)						
Male	6	201.17	2.98 (0.60–5.37)	15	1,489.42	1.01 (0.50–1.52)
Female	5	74.67	6.70 (0.83–12.57)	7	746.33	0.94 (0.24–1.63)
<35 yr	3	74.75	4.01 (0.00–8.56)	6	622.83	0.96 (0.19–1.73)
≥35 yr	8	201.08	3.98 (1.22–6.74)	16	1,612.92	0.99 (0.51–1.48)
<50 yr	9	206.17	4.37 (1.51–7.22)	14	1,380.75	1.01 (0.48–1.55)
≥50 yr	2	69.67	2.87 (0.00–6.85)	8	855.00	0.94 (0.29–1.58)
<65 yr	11	271.50	4.05 (1.66–6.45)	20	1,949.33	1.03 (0.58–1.48)
≥65 yr	0	4.33	0.00 (0.00–0.00)	2	286.42	0.70 (0.00–1.67)

JMDC, Japan Medical Data Center; MDV, Medical Data Vision; PY, patient-years; IR, incidence rate (unique patients with events per 100 PY); CI, confidence interval; CS, corticosteroid; IM, immunosuppressant; TNFi, tumor necrosis factor inhibitor; TAC, tacrolimus; CyA, cyclosporine; 6-MP, 6-mercaptopurine; AZA, azathioprine.